Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Identifying genuine bargains from value traps is something many investors struggle with, which is why we started StockStory - to help you find the best companies. That said, here is one value stock with strong fundamentals and two with little support.
Two Value Stocks to Sell:
8x8 (EGHT)
Forward P/S Ratio: 0.4x
Named after its founding year (1987) with "8x8" representing binary code for communications, 8x8 (NASDAQ: EGHT) provides cloud-based contact center and unified communications solutions that enable businesses to manage customer interactions and internal communications through a single platform.
Why Do We Think EGHT Will Underperform?
- Offerings struggled to generate meaningful interest as its average billings growth of 2.4% over the last year did not impress
- Demand will likely be weak over the next 12 months as Wall Street expects flat revenue
- Operating margin expansion of 2.1 percentage points over the last year shows the company optimized its expenses
8x8’s stock price of $2.18 implies a valuation ratio of 0.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than EGHT.
Luxfer (LXFR)
Forward P/E Ratio: 10.7x
With its magnesium alloys used in the construction of the famous Spirit of St. Louis aircraft, Luxfer (NYSE: LXFR) offers specialized materials, components, and gas containment devices to various industries.
Why Do We Avoid LXFR?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 2.6% annually over the last two years
- Sales are expected to decline once again over the next 12 months as it continues working through a challenging demand environment
- Earnings growth underperformed the sector average over the last five years as its EPS grew by just 2.3% annually
Luxfer is trading at $11.96 per share, or 10.7x forward P/E. To fully understand why you should be careful with LXFR, check out our full research report (it’s free).
One Value Stock to Buy:
Hims & Hers Health (HIMS)
Forward P/E Ratio: 21.2x
Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE: HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products.
Why Should You Buy HIMS?
- Business is winning new contracts that can potentially increase in value as its customer base averaged 29.5% growth over the past two years
- Free cash flow margin expanded by 16.9 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Returns on capital are increasing as management’s prior bets are starting to bear fruit
At $26.29 per share, Hims & Hers Health trades at 21.2x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
